Most likely large-cap and small-cap merger candidates -BofA
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based
Seekingalpha · 17小时前
Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Zacks · 5天前
--UBS Adjusts Charles River Laboratories International Price Target to $378 From $420, Maintains Buy Rating
MT Newswires · 05/05 12:39
--Morgan Stanley Adjusts Charles River Laboratories International's Price Target to $350 from $430, Keeps Overweight Rating
MT Newswires · 05/05 12:21
Research Alert: CFRA Lifts View On Shares Of Charles River Laboratories To Buy From Hold
MT Newswires · 05/05 11:07
--KeyBanc Adjusts Price Target on Charles River Laboratories International to $300 From $390, Keeps Overweight Rating
MT Newswires · 05/05 07:35
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
Zacks · 05/04 15:42
Charles River: Q1 Earnings Insights
Charles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/04 12:21
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:15
Charles River Laboratories Non-GAAP EPS of $2.75 beats by $0.03, revenue of $913.9M beats by $5.26M; updates FY22 guidance
Charles River Laboratories press release (NYSE:CRL): Q1 Non-GAAP EPS of $2.75 beats by $0.03. Revenue of $913.9M (+10.8% Y/Y) beats by $5.26M. The Company is updating its 2022 financial guidance,
Seekingalpha · 05/04 11:05
Charles River Q1 EPS $2.75 Beats $2.71 Estimate, Sales $913.90M Beat $910.10M Estimate
Charles River (NYSE:CRL) reported quarterly earnings of $2.75 per share which beat the analyst consensus estimate of $2.71 by 1.48 percent. This is a 8.7 percent increase over earnings of $2.53 per share from the same
Benzinga · 05/04 11:02
Charles River Laboratories International Q1 Non-GAAP EPS, Revenue Increase; Raises 2022 Revenue Growth Guidance
MT Newswires · 05/04 08:15
-- Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q1 EPS $2.75, vs. Street Est of $2.72
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
Zacks · 05/03 14:34
Preview: Charles River's Earnings
Charles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Charles River will report an earnings per share (EPS) of $2.71.
Benzinga · 05/03 14:11
Charles River Laboratories International's (NYSE:CRL) five-year total shareholder returns outpace the underlying earnings growth
Charles River Laboratories International, Inc. ( NYSE:CRL ) shareholders might be concerned after seeing the share...
Simply Wall St. · 04/28 11:09
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 04/27 19:03
Charles River (CRL) to Report Q1 Earnings: What's in Store?
Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.
Zacks · 04/27 14:24
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
WILMINGTON, Mass. & BOSTON, April 27, 2022--Charles River and Valo have launched Logica, an AI-powered drug solution that translates biological insights into optimized preclinical assets.
Charles River Laboratories International, Inc.是一家提供全方位服务的早期合同研究公司。该公司为帮助制药和生物技术公司、政府机构和学术机构进行研究和药物开发而提供产品和服务。该公司通过两个部门运营：探索及安全评估部门和制造解决方案（制造）部门。探索及安全评估部门包括通过早期开发过程获取药物所需的服务，包括探索服务（一种非监管服务，可帮助客户识别、筛选和选择用于药物开发的先导化合物）以及受监管和不受监管的（良好实验室规范(GLP)和非GLP）安全评估服务。制造部门包括微生物解决方案、生物制剂解决方案和禽疫苗服务。